Mobile

Trial conducted in more then one site to assess safety of the Novartis vaccine against meningititis B injected at 0 and after 2 months in adults at risk because managing meningoccocus type B or travel...

Mise à jour : Il y a 5 ans
Référence : EUCTR2011-003694-29

Trial conducted in more then one site to assess safety of the Novartis vaccine against meningititis B injected at 0 and after 2 months in adults at risk because managing meningoccocus type B or travelling in geographic area where Meningitis B is highly present Studio condotto in piu' centri per valutare la sicurezza del vaccino Novartis contro la meningite B quando somministrato a 0 e dopo due mesi in adulti a rischio poiche' sono a contatto con meningococco di tipo B o viaggiano in aree geografiche dove la meningite B e' altamente presente

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To descriptively assess the safety of Novartis rMenB+OMV NZ in healthy at-risk adults when administered at a 0, 2- month schedule, throughout the clinical study. valutare la sicurezza del vaccino Novartis rmenB+OMV NZ in soggetti sani adulti a rischio con schedula di somministrazione 0-2 mesi

Critère d'inclusion

  • Healthy volunteers (Meningitis B),Volontari sani (Meningite B)

Liens